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Background: Malnutrition is highly prevalent and contributes to mortality in hemodialysis (HD) patients. Although
the receptor for advanced glycation end products (RAGE) system also contributes to the morbidity and mortality of
these patients, the role that the RAGE system plays in determining nutritional status is currently unknown.
Methods: A cross-sectional study examining 79 HD patients was performed. The plasma concentrations of the soluble
RAGE (sRAGE) and S100A12 (also known as EN-RAGE) were studied to evaluate their association with nutritional status,
which was assessed by measuring the mid-thigh muscle mass and subcutaneous fat mass with computed tomography.
Results: Plasma S100A12 concentrations were shown to be significantly and negatively correlated with muscle mass
and with fat mass (r = −0.237, P < 0.05 and r = −0.261, P < 0.05, respectively). In contrast, sRAGE was not shown to
significantly correlate with either of these factors. Multiple regression analyses demonstrated that S100A12 is a significant
independent predictor of both muscle mass and fat mass (P < 0.01 and P < 0.05, respectively).
Conclusions: Our findings suggest that plasma S100A12 levels could play an important role in determining muscle
mass and fat mass in HD patients.
Trial registration: Study number; UMIN000012341.
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Protein-energy wasting (PEW), which is also referred to
as malnutrition, is a condition caused by chronic kidney
disease (CKD) and is characterized by decreased body
stores of protein and energy sources [1]. PEW is present
in a large proportion of advanced CKD patients, in whom
it has been associated with atherosclerotic cardiovascular
disease (CVD), and it has been shown to lead to increased
morbidity and mortality [2,3]. Inadequate nutrition,
inflammation, perturbations of appetite-controlling
hormones, insulin resistance, enhanced proteolysis, and* Correspondence: hfukasawaucsd@gmail.com
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unless otherwise stated.metabolic acidosis may contribute to the pathogenesis of
PEW [4-6].
In the general population, overweight and obesity have
been shown to be significant risk factors for cardiovascular
and all-cause mortality [7]. In contrast, a higher body
mass index (BMI) is associated with decreased mortality
and a reduced risk of hospitalization in hemodialysis (HD)
patients [8,9].
The receptor for advanced glycation end products
(RAGE) has emerged as a central regulator of inflammatory
processes [10]. This multiligand receptor is expressed on
the cell surface, where it can bind to various types of
ligands, including S100/calgranulins, high-mobility group
box 1 (HMGB1) and advanced glycation end products
(AGEs) [11]. The interactions between RAGE and its
ligands activate pro-inflammatory genes, which can cause aral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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complications [11], rheumatoid arthritis [12], inflammatory
bowel disease [13], and Alzheimer’s disease [14].
RAGE accumulates and exists in several forms in
patients with decreased renal function [15,16]. Soluble
RAGE (sRAGE) is a circulating form of RAGE that is
likely generated by the shedding of RAGE bound to the
cell surface. sRAGE has been hypothesized to act as a
decoy receptor by competitively inhibiting the binding of
RAGE ligands to RAGE, thus attenuating downstream
inflammatory responses [17]. One protein that has
been reported to be a ligand for RAGE is S100A12,
which is also known as extracellular newly identified
RAGE-binding protein (EN-RAGE). In contrast to
sRAGE, S100A12 is a natural pro-inflammatory ligand for
RAGE [18,19]. By releasing pro-inflammatory cytokines,
such as interleukin (IL)-1β and tumor necrosis factor
(TNF)-α, S100A12 activates inflammatory responses
[18,20]. Moreover, it enhances the activation and migra-
tion of monocytes/macrophages. Consequently, S100A12
has been suggested to be an important contributor to
the development of inflammatory processes, such as
atherosclerosis [11,20].
Several studies have reported associations between the
RAGE system and CKD. For example, Kim et al. [21] re-
ported that sRAGE is negatively associated with systemic
inflammation and carotid atherosclerosis in peritoneal
dialysis (PD) patients. In addition, Nakashima et al. [22]
and Shiotsu et al. [23] reported that S100A12 might
be a strong predictor for CVD and mortality in HD
patients. However, the potential relationship between
the AGEs-RAGE system and nutritional status has not
been reported in any field, including CKD.
In this study, we report cross-sectional data from a
well-characterized cohort of patients undergoing main-
tenance HD. In addition, we assess the relationships
between plasma RAGE levels and nutritional status by
measuring the areas of mid-thigh muscle and subcutaneous
fat in these patients.
Materials and methods
Subjects
Seventy-nine patients (53 men, 26 women) who had been
undergoing HD at Iwata City Hospital (Shizuoka, Japan)
were enrolled in this cross-sectional study. The causes of
end-stage kidney disease were primary kidney diseases,
such as chronic glomerulonephritis and nephrosclerosis in
65 patients (82%), polycystic kidney disease in six patients
(8%), and overt diabetic nephropathy in 8 patients
(10%). All patients had been subjected to regular HD
for 4–5 hours three times per week at a blood flow
rate of 180–240 ml/min. All patients used bicarbonate
dialysate (Kindaly AF-2E®, Fuso, Osaka, Japan) at a
dialysate flow rate of 500 ml/min. The study protocolwas approved by the institutional ethics committee, and all
patients provided informed consent before participating
in the study.
Anthropometric measurements
Body weight was measured before and after each dialysis
session, and the post-dialysis body weight of each patient
was used as his or her dry weight (DW). BMI (kg/m2)
was calculated by dividing the DW (kg) by the squared
height (m).
Blood sampling and laboratory examinations
Blood samples were drawn at the beginning and end of
the first dialysis session of the week, following a 2-day
interval. Plasma samples were separated immediately
and stored at -80ºC until analyzed. Serum electrolytes, urea
nitrogen, creatinine (Cr), albumin, cholesterol, triglyceride,
and C-reactive protein (CRP) levels were measured using
standard laboratory techniques with an auto-analyzer.
Plasma S100A12 and sRAGE levels were measured
using enzyme-linked immunoassays (the CircuLex
S100A12/EN-RAGE ELISA kit; CycLex, Nagano, Japan,
and the Human RAGE Quantikine ELISA Kit; R&D
Systems, Minneapolis, MN, USA, respectively). A single-
pool urea kinetic model was used to calculate the protein
catabolic rate and the delivered dialysis dose, [clearance of
urea (K; mL/min) multiplied by the time on dialysis
(t; min) divided by the volume of distribution for urea
(Vurea; mL)], as described by Depner and Daugirdas [24].
Measurements of muscle and fat areas by computed
tomography (CT)
Axial CT images of the thigh were obtained at the
midpoint of a line extending from the superior border
of the patella to the greater trochanter of the femur
[25,26]. Each patient was examined in the supine position
with his or her thigh muscle relaxed. The thickness of
each slice was 10 mm. Radiographic images were digitally
scanned for analysis with a personal computer. The
adipose-tissue-free thigh muscle area (TMA) and thigh
subcutaneous fat area (TSFA) were measured using
NIH-IMAGE, a public domain planimetry program
available from the National Institutes of Health (written
by Wayne Rasband, The National Institutes of Health,
Bethesda, MD, USA). To avoid the potentially confounding
influence of body size, we also standardized TMA and
TSFA by dividing by DW (TMA/DW ratio and TSFA/DW
ratio, respectively) [26].
Statistical analysis
Data were expressed as the mean ± standard deviation (SD)
for continuous variables, with normal distributions or the
median and interquartile range (25th to 75th percentiles)
for data with skewed distributions. The threshold for
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sons between two groups were performed using the
Mann–Whitney U-test, and comparisons between the
three groups were made using the Kruskal-Wallis test.
Spearman’s rank-order correlation analysis was used to
evaluate the potential associations between TMA/DW,
TSFA/DW, sRAGE, or S100A12 with the selected param-
eters. Multivariate regression analyses were used to assess
the independent predictors of TMA/DW and TSFA/DW.
All statistical analyses were performed using SPSS statis-
tical software, version 19.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinical profiles
Table 1 presents the characteristics of the study population.
The median age was 67.0 years (the 25th to 75th percentile
ranged from 60.0 to 73.5 years). The median dialysis vintage
was 138.0 months (range, 43.5 to 268.0 months), and the
mean BMI was 20.5 ± 2.9 kg/m2.Table 1 Patient Characteristics
Variables Total (n = 79)
Age, years 67.0 (60.0 to 73.5)
Dialysis vintage, months 138.0 (43.5 to 268.0)
Height, cm 160.2 ± 8.8
Dry weight, kg 50.7 ± 9.8
BMI, kg/m2 20.5 ± 2.9
Total protein, g/dL 6.4 ± 0.4
Serum albumin, g/dL 3.7 ± 0.4
Total cholesterol, mg/dL 152.1 ± 34.3
LDL choresterol, mg/dL 85.2 ± 21.1
Blood urea nitrogen, mg/dL 62.6 ± 12.7
Serum creatinine, mg/dL 10.8 ± 2.7
Calcium, mg/dL 9.4 ± 0.9
Phosphate, mg/dL 5.0 ± 1.3
Intact PTH, pg/mL 102.5 ± 107.4
β2-microglobulin, mg/L 26.7 ± 6.6
Kt/Vurea 1.6 ± 0.3
nPCR, g/kg/ideal body weight/day 0.97 ± 0.17
CRP, mg/dL 0.1 (0.0 to 0.3)
sRAGE, pg/mL 1550.4 (1005.3 to 2336.5)
S100A12, ng/mL 32.3 (22.4 to 53.5)
TMA, cm2 75.7 (62.7 to 95.2)
TMA standardized for DW 1.53 (1.41 to 1.75)
TSFA, cm2 33.3 (23.2 to 47.2)
TSFA standardized for DW 0.64 (0.47 to 0.87)
aSignificantly different from men, P < 0.05.
bSignificantly different from men, P < 0.01.
cSignificantly different from men, P < 0.001.
All variables were expressed as the mean ± SD or the median and interquartile ran
Abbreviations: LDL low-density lipoprotein, Kt/Vurea amount of dialysis delivered to eNo significant sex differences were observed with respect
to the age, dialysis vintage, or serum albumin levels of the
study participants. However, the patient height, DW, BMI,
and serum Cr levels were all shown to be significantly
greater in men than in women. In addition, TMA and
TMA standardized for DW (TMA/DW) were both
significantly greater in men than in women, whereas
TSFA and TSFA standardized for DW (TSFA/DW) were
significantly greater in women than in men. No significant
differences in the levels of CRP, sRAGE, and S100A12
were observed between men and women.
Correlations between TMA/DW, TSFA/DW, sRAGE, and
S100A12 levels and the clinical parameters
Significant positive correlations were observed between
TMA/DW and the serum levels of albumin (P < 0.001) and
creatinine (P < 0.001). In addition, TMA/DW was nega-
tively correlated with age (P < 0.05) and Kt/Vurea (P < 0.05)
(Table 2). TMA/DW was also negatively associated withMen (n = 53) Women (n = 26)
68.0 (60.0 to 74.0) 65.5 (59.8 to 71.5)
134.0 (40.0 to 267.0) 157.5 (85.8 to 282.5)
164.2 ± 6.3 152.1 ± 7.5c
56.5 ± 9.4 43.5 ± 7.4c
20.9 ± 2.8 19.6 ± 3.0a
6.4 ± 0.4 6.4 ± 0.4
3.6 ± 0.4 3.7 ± 0.4
145.1 ± 33.9 166.3 ± 31.1a
82.5 ± 21.4 90.8 ± 19.6
64.8 ± 10.9 58.2 ± 15.1a
11.2 ± 3.0 9.8 ± 1.7b
9.3 ± 0.9 9.7 ± 0.8
5.1 ± 1.4 4.8 ± 1.2
90.5 ± 59.2 127.0 ± 166.6
26.4 ± 6.6 27.3 ± 6.7
1.5 ± 0.2 1.9 ± 0.3c
0.98 ± 0.15 0.94 ± 0.21
0.1 (0.1 to 0.4) 0.0 (0.0 to 0.1)
1496.3 (950.0 to 2407.9) 1704.4 (1072.6 to 2240.6)
33.4 (24.1 to 56.9) 25.3 (18.6 to 39.3)
88.2 (69.0 to 99.7) 60.9 (54.8 to 72.6)c
1.57 (1.44 to 1.79) 1.45 (1.24 to 1.63)a
27.2 (19.6 to 40.8) 46.9 (31.1 to 59.4)c
0.53 (0.42 to 0.67) 1.05 (0.75 to 1.39)c
ge (25th to 75th percentiles).
ach patient per treatment.
Table 2 Correlations between TMA/DW, TSFA/DW, and





Age −0.294a −0.113 −0.032 0.138
HD vintage −0.023 −0.066 0.115 −0.231a
BMI 0.033 0.266a −0.232a 0.020
Total protein −0.032 −0.013 0.088 0.033
Serum albumin 0.394c 0.206 0.117 −0.294b
Total cholesterol 0.177 0.341b −0.092 −0.011
LDL chlesterol 0.080 0.270a −0.120 0.023
Blood urea nitrogen 0.097 −0.154 −0.004 0.059
Serum creatinine 0.444c 0.042c 0.181 −0.111
Intact PTH 0.064 −0.022 −0.117 −0.147
β2-microglobulin −0.151 0.074 0.209 0.282a
Kt/Vurea −0.203
a 0.265a 0.151 −0.072
nPCR 0.040 −0.109 0.017 0.041
CRP −0.269a −0.343b −0.211 0.478c
TMA/DW - −0.072 0.112 −0.237a
TSFA/DW −0.072 - 0.033 −0.261a
Log sRAGE 0.112 0.033 - −0.088
Log S100A12 −0.237a −0.261a −0.088 -
The data represent the correlation coefficients.
aP < 0.05, bP < 0.01, cP < 0.001.
Abbreviations: TMA/DW TMA standardized for DW, TSFA/DW TSFA standardized
for DW, LDL low-density lipoprotein, Kt/Vurea amount of dialysis delivered to
each patient per treatment.
Figure 1 Associations between (A) TMA standardized for DW and
plasma S100A12 levels and (B) TSFA standardized for DW and
plasma S100A12 levels.
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(P < 0.05, Figure 1A). Significant positive correlations were
observed between TSFA/DW and the BMI (P < 0.05), total
cholesterol (P < 0.01), LDL cholesterol (P < 0.05), serum
creatinine (P < 0.001) and Kt/Vurea (P < 0.05) levels.
However, TSFA/DW was negatively correlated with the
CRP (P < 0.01) and log-transformed S100A12 (P < 0.05,
Figure 1B) levels. Following log transformation, the
sRAGE levels were shown to be negatively associated
with BMI, but no significant associations were observed
with TMA/DW and TSFA/DW, or the log-transformed
S100A12 level. However, significant negative correlations
were observed between the log-transformed S100A12
levels and HD vintage (P < 0.05), serum albumin (P < 0.01),
TMA/DW (P < 0.05, Figure 1A), and TSFA/DW (P < 0.05,
Figure 1B). In contrast, positive correlations were observed
between log-transformed S100A12 levels and the levels of
β2-microglobulin (P < 0.05) and CRP (P < 0.001).
Determinants of potential biomarkers of muscle and/or
fat mass
Multiple regression analyses revealed that log-transformed
S100A12 was independently associated with TMA/DW
and TSFA/DW when log-transformed S100A12, age, sex(model 1), HD vintage, BMI (model 2), total cholesterol,
and CRP (model 3) were included as independent vari-
ables (Table 3).
Furthermore, when S100A12 levels were divided
into three tertiles [S100A12 < 24.0 (n = 26), 24.0 ≤
S100A12 < 44.0 (n = 27), and S100A12 ≥ 44.0 ng/mL
(n = 26)], then TMA/DW and TSFA/DW were significantly
decreased (Table 4).
Discussion
The primary finding of this study is that high plasma
levels of S100A12 are independently associated with low
mid-thigh muscle mass and low subcutaneous fat mass in
HD patients, even after adjusting for potential confounding
variables. To our knowledge, this study is the first to
determine the role that the RAGE system plays in the
nutritional status of patients with advanced CKD.
Advanced CKD patients often suffer from nutritional
problems that are associated with increased morbidity
Table 3 Multiple regression analysis with TMA standardized
for DW or TSFA standardized for DW as the dependent
variables and S100A12, Age, Sex, HD vintage, BMI, total
cholesterol, and CRP as the independent variables
Model 1 Model 2 Model 2
Variable β P β P β P
Dependent variable: TMA standardized for DW
Log S100A12 −0.305 0.004 −0.327 0.003 −0.312 0.004
Age −0.242 0.019 −0.252 0.015 −0.215 0.034
Sex 0.369 <0.001 0.386 <0.001 0.4572 <0.001
HD vintage - - −0.094 0.383 −0.094 0.371
BMI - - −0.099 0.361 −0.122 0.247
Total cholesterol - - - - 0.227 0.031
CRP - - - - −0.144 0.159
Dependent variable: TSFA standardized for DW
Log S100A12 −0.191 0.026 −0.167 0.025 −0.181 0.014
Age 0.028 0.737 0.052 0.471 0.074 0.295
Sex −0.659 <0.001 −0.744 <0.001 −0.695 <0.001
HD vintage - - 0.035 0.639 0.039 0.601
BMI - - 0.397 <0.001 0.378 <0.001
Total cholesterol - - - - 0.152 0.041
CRP - - - - −0.042 0.563
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to describe the state of decreased body stores of protein
and energy (i.e., muscle and fat mass) that occurs in CKD.
In fact, HD patients have been reported to exhibit lower
BMIs than age- and sex-matched control subjects from
the general population [28]. Based on this observation,
several studies have shown that increased BMI contributes
to survival advantages in dialysis patients [8,9]. Because
increased BMI has been associated with an increased risk
of cardiovascular disease and all-cause mortality in the
general population [7], this opposite relationship that is
observed in dialysis patients is known as “risk factor
paradox” or “reverse epidemiology” [29,30].
In dialysis patients, increased serum Cr levels have
been associated with improved survival, whereas lower











1.63 ± 0.23 1.60 ± 0.29 1.42 ± 0.27 P < 0.05
TSFA standardized
for DW
0.88 ± 0.48 0.72 ± 0.36 0.58 ± 0.22 P < 0.05
The numbers in parentheses delineate the range for each S100A12 group.
Data of TMA and TSFA standardized for DW (TMA/DW and TSFA/DW,
respectively) are shown as the mean ± SD.mortality [31-33]. This finding suggests that low serum
levels of Cr as a proxy for low muscle mass could be
associated with adverse outcomes [31]. Carrero et al. [34]
also reported that muscle wasting measured by subjective
global assessment (SGA) is associated with the increased
mortality. These observations suggest that muscle mass is
an important predictor of mortality in HD patients.
However, increased fat mass has been associated with a
lower risk of mortality and a reduced risk of hospitalization
in HD patients [35]. Moreover, Kakiya et al. [36] showed
that a decrease in body fat is associated with an increased
risk of death in these patients. Currently, it remains to be
determined whether the survival advantage associated
with higher BMI in dialysis patients is caused by increases
in muscle mass, fat mass, or both. One reason that this
question remains unanswered is because BMI cannot
differentiate between weight changes caused by muscle
mass alterations and weight changes resulting from fat
mass or water weight [8]. Previously, Beddhu et al. [37]
attempted to investigate this issue using 24-hour urinary
creatinine excretion as a surrogate for muscle mass. Based
on their analysis, Beddhu and colleagues hypothesized that
muscle mass might be a more important contributor
to this survival advantage than fat mass. However,
additional studies that directly measure muscle mass
and fat mass are required to clarify this issue.
AGEs are generated as a result of chronic hyperglycemia
and enhanced oxidative stress [38,39]. AGEs were initially
thought to be the primary active ligands for their receptors,
such as RAGE, but several new ligands, including the
high-mobility group box proteins, S100 proteins, and
amyloid fibrils, have been recently identified [40]. The
binding of these ligands to RAGE induces oxidative
stress, inflammation, and extracellular matrix accumulation
[39,41]. Because the plasma AGE level changes that are
observed in CKD patients are relatively modest [42], ligands
other than AGEs for RAGE may be more important in
developing RAGE-mediated complications in CKD. For
example, S100A12, which is also known as EN-RAGE,
has been identified as an interesting pro-inflammatory
ligand for RAGE that triggers the RAGE pathway.
S100A12 activates key inflammatory signals, such as
nuclear factor-κB (NF-κB), and it stimulates the produc-
tion of pro-inflammatory cytokines, such as IL-1β and
TNF-α [18,20]. In contrast, sRAGE, which acts as a decoy
receptor for RAGE ligands, suppresses RAGE-mediated
inflammatory responses [17]. Recently, several studies
have focused on the pivotal role of RAGE signaling in
patients with CKD [15,21-23]. For example, sRAGE is
negatively associated with systemic inflammation and
with carotid intima-media thickness in PD patients [21].
In addition, S100A12 has been shown to predict the
cardiovascular and all-cause mortality in HD patients
[22,23]. In the present study, S100A12 was shown to be
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and fat mass by both univariate and multivariate analysis,
whereas no such relationships were observed for sRAGE.
Thus, our study reveals the potential value of S100A12 as
a predictor of nutritional status and provides clinical
evidence regarding its possible role in the develop-
ment of PEW in HD patients. In contrast, our data
indicate that sRAGE levels are likely of limited clin-
ical value in identifying PEW patients, although this
possibility should be tested in a specifically designed
clinical trial.
Another key finding from the present study is that the
negative associations of S100A12 with muscle mass and
fat mass both still remain significant even after adjusting
for systemic inflammation (Table 3). As reported previ-
ously, systemic inflammation can cause a decrease in
muscle mass because pro-inflammatory cytokines can
contribute to anorexia, inhibit protein synthesis and pro-
mote catabolism [30]. Adipose tissue is a well-known
source of pro-inflammatory cytokines, and obese CKD
patients have actually been shown to exhibit higher
levels of inflammation [43,44]. These findings highlight
the difficulty of using inflammation as the sole explan-
ation for the observed reductions of muscle and fat
mass. Therefore, to clarify the influence of S100A12 on
PEW in dialysis patients, we tried to adjust for the levels
of systemic inflammation. Our analysis revealed that
S100A12 is a direct predictor of muscle and fat mass
independent of systemic inflammation. Previously,
Hofmann et al. [45] demonstrated that S100A12 reduces
cellular proliferation and increases H2O2 production via
the NADPH oxidase system. Together, our results suggest
that high levels of plasma S100A12 are associated
with PEW via non-inflammatory mechanisms, such as
oxidative stress. Further basic studies are warranted
to clarify the precise role of this interesting ligand in
determining nutritional status.
Our study has several limitations. First, due to the cross-
sectional study design, a longitudinal causal relationship
cannot be established between the changes in plasma
S100A12 levels and alterations in muscle and/or fat mass.
Second, because of the relatively small number of patients
in our cohort, the generalizability of our conclusions
remains unclear, and our data should be confirmed
by larger studies.
Conclusions
S100A12 is significantly and negatively associated with
both muscle mass and fat mass in HD patients. Our
findings suggest that plasma S100A12 levels could play
an important role in determining the nutritional status
of HD patients. Future longitudinal observations and
interventional studies are warranted to establish whether
this link is causal in nature.Abbreviations
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